GlycoMimetics, a clinical-stage biotech firm, is making strides in the field of glycobiology-based therapies for cancers and inflammatory diseases in the United States. Notably, the company is developing uproleselan, an E-selectin antagonist that is used alongside chemotherapy to treat acute myeloid leukemia (AML), and is currently undergoing a phase 3 trial to treat relapsed/refractory AML. Additionally, the company is working on multiple other programs including GMI-1687, an antagonist of E-selectin for the treatment of vaso-occlusive crisis, and galectin-3 antagonists, a carbohydrate-binding protein. GlycoMimetics is also in the process of developing GMI-1359, a treatment that targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics was founded in 2003 and is based in Rockville, Maryland.
GlycoMimetics Inc's ticker is GLYC
The company's shares trade on the NASDAQ stock exchange
They are based in Rockville, Maryland
There are 51-200 employees working at GlycoMimetics Inc
It is glycomimetics.com
GlycoMimetics Inc is in the Healthcare sector
GlycoMimetics Inc is in the Biotechnology industry
The following five companies are GlycoMimetics Inc's industry peers: